GlaxoSmithKline plc (GSK) Receives “Neutral” Rating from Citigroup Inc.

Citigroup Inc. restated their neutral rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note released on Thursday.

A number of other research analysts have also recently issued reports on the stock. Liberum Capital restated a buy rating and set a GBX 1,760 ($23.15) price objective on shares of GlaxoSmithKline plc in a report on Thursday. Beaufort Securities decreased their price objective on shares of GlaxoSmithKline plc from GBX 1,800 ($23.67) to GBX 1,450 ($19.07) and set a buy rating for the company in a report on Wednesday, November 8th. Investec cut shares of GlaxoSmithKline plc to a hold rating and decreased their price objective for the company from GBX 1,800 ($23.67) to GBX 1,390 ($18.28) in a report on Monday, November 6th. Morgan Stanley set a GBX 1,450 ($19.07) price objective on shares of GlaxoSmithKline plc and gave the company a sell rating in a report on Monday, November 6th. Finally, Berenberg Bank decreased their price objective on shares of GlaxoSmithKline plc from GBX 1,835 ($24.14) to GBX 1,760 ($23.15) and set a buy rating for the company in a report on Thursday, November 2nd. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 1,574.25 ($20.71).

Shares of GlaxoSmithKline plc (GSK) traded up GBX 1 ($0.01) during trading hours on Thursday, hitting GBX 1,319 ($17.35). 9,175,386 shares of the stock traded hands, compared to its average volume of 9,590,000. GlaxoSmithKline plc has a 12 month low of GBX 1,315.50 ($17.30) and a 12 month high of GBX 1,724.50 ($22.68).

GlaxoSmithKline plc (LON:GSK) last issued its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping the consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). GlaxoSmithKline plc had a net margin of 17.79% and a return on equity of 461.88%. The company had revenue of GBX 784.30 billion during the quarter.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/11/13/glaxosmithkline-plc-gsk-receives-neutral-rating-from-citigroup-inc.html.

The firm also recently disclosed a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.

In other news, insider Urs Rohner bought 473 shares of the stock in a transaction that occurred on Wednesday, October 25th. The shares were acquired at an average cost of GBX 1,518 ($19.97) per share, for a total transaction of £7,180.14 ($9,443.82). Also, insider Simon Dingemans bought 1,076 shares of the stock in a transaction that occurred on Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.08) per share, for a total transaction of £16,430.52 ($21,610.57). In the last three months, insiders bought 1,576 shares of company stock worth $2,400,376.

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply